Børsen: After the hearing – Novo Nordisk is vulnerable in the USA
CEO of Novo Nordisk, Lars Fruergaard Jørgensen, was not comfortable in the hot seat during the hearing at the American health committee on Tuesday. Next year, Ozempic will be part of price negotiations that worry Novo Nordisk investors.